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Eva Guinan,1 Leo Luzmik,2 Rupert Handgretinger,3 Ann Woolfrey4An important barrier to the success of transplanting haploidentical hematopoietic stem cells is delayed re-
constitution of immune cells that provide protection from opportunistic infections and recurrent malignancy.
In recent years a large research effort has been directed toward improving immune reconstitution through
methods that potentially spare these cells while simultaneously reducing the alloreactive lymphocytes that
cause graft-vs.-host disease. The basic concepts that support three very different approaches to selective de-
pletion of haploidentical grafts are described in this section. Twomethods take advantage of the proliferation
of donor T cells after encountering alloantigen, and the third method exploits newer technology to engineer
a graft that excludes alloreactive T cells while preserving other immunomodulatory cells.
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Initial attempts to transplant unmodified (T-
replete) haploidentical bone marrow were associated
with severe, often lethal, graft rejection or graft-ver-
sus-host disease (GVHD) as a consequence of exces-
sive alloreactivity of host and donor T cells [1,2].
Tremendous strides have been made since, such that
a haploidentical donor is now a reasonable option for
the many patients without a closely matched related
or unrelated donor. In the 1970s and 1980s, various
methods were perfected to deplete T cells from the
donor graft, which markedly reduced the risk for
GVHD.However, it soon became apparent that donor
T cells play an important role in preventing graft rejec-
tion by eliminating or inactivating recipient alloactive
cells that remain functionally active after the pretrans-
plant conditioning. Graft rejection, resulting from the
paucity of T cells in the graft, became the main obsta-
cle to success; but by the late 1990s this complication
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6/j.bbmt.2009.11.015of very intensive immunosuppressive regimens, and
in adults by transplantation of very large numbers of
hematopoietic stem cells found in mobilized periph-
eral blood (PB) [3,4].
Currently the most important barrier to the suc-
cess of haploidentical hematopoietic cell transplant
(HCT) is the lack of expedient immune reconstitution,
leading to opportunistic infections and relapse. Severe
depletion of T lymphocytes removes virus-specific
cytotoxic T lymphocytes (CTLs) and other
immunomodulatory cells important in controlling
malignancies[5]. This article focuses on the develop-
ment of selective depletion processes with the aim of
enhancing immune reconstitution following haploi-
dentical HCT. Two methods take advantage of the
proliferation of donor T cells after encountering allo-
antigen: 1 of these induces anergy in alloreactive T
cells within the graft by blocking costimulatory sig-
nals, whereas the other takes advantage of the relative
sensitivity of alloreactive T cells, compared to hemato-
poietic stem cells (HSC), to high-dose cyclophospha-
mide given in vivo. The third method exploits newer
technology to engineer a graft that includes high num-
bers of natural killer (NK) cells and other immuno-
modulatory cells, as well as high numbers of HSCs.COSTIMULATORY BLOCKADE: MORE THAN
ONE MECHANISM LEADS TO DECREASED
ALLOREACTIVITY (EVA GUINAN)
Alloreactive T cells, defined by response to PB
stimulators and therefore without representation of
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comprise only 0.1% to 3% of the peripheral blood
pool. Therefore, the vast majority of depleted T cells
have no role inGVHD but represent other crucial rep-
ertoire. One obvious solution to the problem of
delayed immune reconstitution is selective depletion
limited to alloreactive donor T cells [6,7]. Selective de-
pletion methodologies use ex vivo mixed lymphocyte
reactions (MLR) to stimulate donor T cells with recip-
ient cells. Reactive cells (defined by cell surface or in-
tracellular changes) are physically removed from the
T cell pool.
Induction of alloantigen-specific tolerance in the
reactive cells offers an alternative approach [8]. There
are multiple mechanisms for inducing tolerance in hu-
man T cells. One well-studied approach derives from
recognition that 2 different signals are required to ac-
tivate T cells, the first resulting from major histocom-
patibility complex (MHC) restricted antigen binding
to a specific T cell receptor and the second resulting
from nonspecific but requisite costimulation by the an-
tigen-presenting cell (APC) [9]. In humans, costimula-
tion provided by the ligands B7.1 and B7.2 (CD80 and
CD86) on APC with the CD28 receptor (present on
95% of CD41 T cells) appears sufficient to produce
full activation and function. Blockade of the APC cos-
timulatory signal concurrent with delivery of a first
antigen specific signal to T cells results in antigen-
specific hyporesponsiveness on rechallenge [10]. This
is termed anergy or tolerance. Anergy does not require
ongoing costimulatory blockade, and leaves the re-
maining T cell repertoire (ie, the function of T cells
that had not received a first signal during anergy induc-
tion) intact. In the transplant setting, donor T cells can
be stimulated ex vivo with a source of recipient alloan-
tigens by performing a donor:recipient MLR in the
presence of molecules blocking B7 family ligation of
CD28. This can be achieved by use of first- or sec-
ond-generation Ig-fusion proteins of the high affinity
ligand for B7.1/2, CTLA4, or by antibodies to B7.1
and B7.2 [10,11].
Costimulatory blockade during MLR results in
activation of an alternative intracellular signaling cas-
cade than that activated when both signal 1 and 2 are
intact [12]. One result of this process is a dramatic de-
crease in IL-2 and IL-4 transcription and subsequent
secretion, manifest as reduced proliferation of donor
T cells during this primary culture. Moreover, donor
T cells exhibit profound hyporesponsiveness (anergy)
when reexposed to APC from the same stimulator,
with 85% to 98% inhibition of proliferation. This
approach reduces stimulator specific proliferation by
both CD41 and CD81 responder T cells [13]. Ex
vivo anergization of haploidentical family member
donor bone marrow, complete with 107-108 contami-
nating donor T cells/kg, has been undertaken in clini-
cal trials in which either CTLA4-Ig (n5 19) oranti-B7.1 and anti-B7.2 humanized antibodies (n5 5)
were used to provide blockade of CD28-mediated cos-
timulation [13,14]. Irradiated recipient PBMC were
used as allostimulators. Patients receiving these alloa-
nergized haploidentical grafts were observed to have
less than the expected rate of GVHD despite the large
number of mature donor T cells infused. Perhapsmore
striking, however, in these admittedly small cohorts,
was the paucity of opportunistic infection, relapse,
and chronic GVHD (cGVHD) observed. The former
may be attributable in part to several related factors,
such as relative freedom from GVHD and immuno-
suppressive medication. However, anergization
supports persistence of mature donor T cells with rep-
ertoire relevant to the immediate port transplant
course, such as response to cytomegalovirus (CMV)
and other herpes family viruses as well as response to
the tumor antigen WT1.6 Functional pathogen and
tumor specific responses are retained by both C41
and CD81 cells.
The recipients of anergized bone marrow (BM)
transplants also had striking expansion of T regulatory
(Treg) cells in the early posttransplant period, and
levels of Treg above baseline were retained for an ex-
tended period. Treg levels were greater than those
shown in human observational studies to be associated
with decreased acute GVHD (aGVHD) and cGVHD.
Whereas Treg isolated from the PB of conventional al-
logeneic BMT recipients have demonstrated global
suppressive activity, the Treg present in the patients
given anergized T cells demonstrated suppression spe-
cific to recipient alloantigens. Published in vitro
models have strongly suggested a role for Treg in sup-
pression of alloresponses after alloanergization [15].
Exploring this question in samples from our patients
and from normal donors disclosed that alloanergiza-
tion bymeans of costimulatory blockade indeed gener-
ated Treg and that these were recipient allospecific.
Reexposure to alloantigen (ie, conduct of a secondary
MLR to mimic the reexposure of ex vivo anergized
donor T cells to recipient alloantigens upon infusion
into the transplant recipient) resulted in significant in-
creases in both the number and the potency of this al-
lospecific Treg population. Thus, there appear to be at
least 2 potent and potentially synergistic mechanisms by
which blockade of CD28 mediated costimulation con-
trols alloreactivity transplantation of alloanergized
donor T cells.
Thus, costimulatory blockade offers a multifaceted
approach to control of alloreactive cells with sparing of
pathogen and tumor specific repertoire. Both labora-
tory and clinical exploration will be needed to fully
understand the implications of these dual mechanisms
in relation to optimal cell-based strategies for prophy-
laxis and treatment of aGVHD and cGVHD and
improving the tempo and breadth of immune reconsti-
tution after HSCT. Additional roles in solid organ
Figure 1. Activated T cells are relatively more sensitive to the effects of cyclophosphamide compared to resting T cells. Following nonmyeloablative
conditioning, both donor and host T cells are exposed to alloantigens, resulting in activation and proliferation of T cells capable of host-versus-graft and
graft-versus-host reactions. Expansion of the alloreactive clones occurs in the first 3 days after transplant, at which point cyclophosphamide is given to
deplete activated T cells. Hematopoietic stem cells and resting T cells are relatively resistant to cyclophosphamide, which preserves T cells that rec-
ognize viral antigens and enhances immune reconstitution.
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further interest.POSTTRANSPLANT CYCLOPHOSPHAMIDE:
TOLERANCE INDUCTION OF
ALLOREACTIVE T CELLS (LEO LUZNIK)
Studies in the mouse model suggest that allo
HSCT induces bidirectional activation and prolifera-
tion of alloreactive host-versus-graft (HVG) and
graft-versus-host (GVH) T cells, and that these
recently activated T cells are more susceptible to cy-
clophosphamide than resting T cells (Figure 1) [16].
Tolerance to histocompatibility antigens can be in-
duced if cyclophosphamide is administered after allog-
rafting; however, it must be given in high doses 2 to
3 days after alloantigen exposure [16,17]. Tolerance
is not induced if the same high dose of cyclophospha-
mide is given 4 or more days after transplantation.
This ability of high-dose cyclophosphamide to induce
tolerance to histocompatibility antigens provides an
example of the phenomenon of drug-induced immu-
nologic tolerance. Strauss et al. [18] have shown that
cyclophosphamide and methotrexate are agents used
in clinical practice, which can induce apoptosis of
alloreactive T cells, a mechanistic prerequisite for the
induction of tolerance.
Based on these studies, it is reasonable to hypoth-
esize that administration of high-dose cyclophospha-
mide after transplant can induce tolerance
simultaneously in both recipient and donor T cells,
thus facilitate engraftment and reduce the incidenceof GVHD. In mice conditioned with a reduced-inten-
sity regimen of fludarabine and 200 cGy total-body
irradiation (TBI), a single dose of posttransplantation
cyclophosphamide (200 mg/kg) augmented the
engraftment of major histocompatibility complex
(MHC)-mismatched bone marrow [19]. In addition,
posttransplantation cyclophosphamide reduced the in-
cidence and severity of GVHD across MHC barriers
after myeloablative conditioning. This latter observa-
tion was not entirely new, because cyclophosphamide
administration was one of the first strategies shown
to be effective in controlling aGVHD in rodent
models. However, in an early clinical trial, cyclophos-
phamide given in multiple small doses to patients al-
lografted with HLA-matched sibling bone marrow
was found to be inferior to cyclosporine in preventing
GVHD [20]. In retrospect, cyclophosphamide may
have been given at the wrong time or at a dose that
was too low to be maximally effective at suppressing
GVHD. Results of the more recent preclinical work,
however, indicates that the primitive HSC is fairly re-
sistant to high-dose cyclophosphamide, and provides
the rationale to test this approach in the clinical setting
[21].
Two independent clinical trials evaluated the
safety and efficacy of high-dose, posttransplantation
cyclophosphamide, given in conjunction with myco-
phenolate mofetil (MMF) and tacrolimus after non-
myeloablative conditioning [22,23]. All patients were
treated in outpatient setting and received conditioning
modified from the regimen developed by Storb and
colleagues, followed by T cell-replete donor bone
marrow on day 0, and 50 mg/kg of cyclophosphamide
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Administration of tacrolimus and MMF was not initi-
ated until the day following to avoid blocking cyclo-
phosphamide-induced tolerance. The median times
to neutrophil and platelet recovery were 15 and 24
days, respectively. Graft failure occurred in 9 of 66
(13%) evaluable patients, and was fatal in 1. The
cumulative incidences of acute grade II-IV and grade
III-IV GVHD were 34% and 6%, respectively. The
cumulative incidence of nonrelapse mortality (NRM)
at 1 year was 15%. There was a trend toward a lower
incidence of extensive cGVHD among recipients of
2 versus 1 dose of posttransplant cyclophosphamide
(5% versus 25%, P5 .05), the only difference in out-
comes between these 2 groups of patients. Serious
infections were relatively infrequent: there were no
cases of CMV disease and only 5 cases of invasive fun-
gal infection, 2 of which were fatal. These encouraging
outcomes in patients with advanced hematologic
malignancies served as a rationale to examine the
applicability of this strategy in patients with life-
threatening nonmalignant hematologic diseases [24].
Engraftment was achieved in 2 patients with throm-
botic paroxysmal noctural hemoglobinuria (PNH), 1
of whom also had sickle cell disease, demonstrating
proof of principle. Currently, a clinical trial is testing
the efficacy of this approach in adult patients with
sickle cell disease (Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins) and in children
with primary immunodeficiency states (Fred Hutchin-
son Cancer Center).
Several conclusions can be made from these early
studies. First, posttransplantation immunosuppression
with high-dose cyclophosphamide, tacrolimus, and
thrice daily MMF is associated with an acceptably
low incidence of graft rejection after nonmyeloablative
conditioning. Of equal importance, nearly all patients
with graft rejection eventually recovered autologous
hematopoiesis. Second, this approach is associated
with a low incidence of aGVHD and cGVHD. The
low incidence of cGVHD is especially appealing to
patients with nonmalignant disorders. Third, it also
appears that this strategy may allow the preservation
of fertility in young females. Finally, this approach
may improve immune reconstitution, which may
reduce the incidence of life-threatening opportunistic
infections.REDUCED-INTENSITY CONDITIONING (RIC)
AND CD3/19 DEPLETION: AUGMENTATION
OF NK FUNCTION (RUPERT
HANDGRETINGER)
An interesting development in the field was the
introduction of the megadose concept to overcome
the HLA barrier and the use of mobilized peripheralstem cells (PBSCs) instead of bone marrow as the
stem cell source [4]. The positive selection of
CD341 stem cells was introduced as an efficient
large-scale clinical indirect method for T cell deple-
tion and a number of clinical studies using peripheral
CD341 stem cells were performed in adults and chil-
dren [4,25]. Although CD341 positive selection
methods have widely been used to indirectly deplete
T and B cells from mobilized peripheral stem cell
grafts, negative T cell-depletion strategies might offer
some advantages in overcoming the HLA barrier with
RICwhilemaintaining an effective graft-versus-malig-
nancy effect. Results of clinical trials using megadose
CD341-selected haploidentical peripheral blood
stem cells (PBSC) have pointed to the importance of
alloreactive natural killer (NK) cells in the context of
HLA-mismatched haploidentical grafts [26]. Alloreac-
tive NK cells not only have significant antileukemic
activity in patients but are also able to enhance engraft-
ment in a murine model in the context of RIC.
Therefore, it seems reasonable to hypothesize that
cotransplantation of large numbers of NK cells to-
gether with mobilized PBSCs would support engraft-
ment and exert antileukemic effects, and might
facilitate the use of RIC regimens.
The positive selection of CD341 stem cells results
in efficient depletion of all CD342 negative cells, in-
cluding T and B cells. In contrast, the removal of
T and B cells from the PBSCs via CD3/192 negative
depletion also leads to an efficient T/B-depletion, but
retains all other cells not expressing the CD3 and
CD19 antigen. In Figure 2, the fundamental difference
between positive selection and negative T and B cell
depletion is shown. Although CD341 positively
selected cells are a homogenous population (Figure 2,
left panel), the CD3/19-depleted cells are a heteroge-
nous population consisting of lymphoid and myeloid
cells (Figure 2, right panel). Such CD3/19-depleted
grafts contain large numbers of CD561/CD32 NK
cells and other monocytic/myeloid cells. Analysis of
CD3/19-depleted PBSCs obtained from 27 haploi-
dentical donors for 27 pediatric patients found the
average number of contaminating T and B cells to be
low, with a median 49 103 CD31/kg recipient body
weight (range 7-200 103/kg) and median 20 103
CD191/kg (range: 2-47  103/kg). In contrast, large
numbers of CD341 cells median 16 106/kg, range:
7-41 106/kg), CD561/CD32 NK cells (median
137 106/kg, range: 9-550 106/kg), and myeloid
cells (median 620 106/kg, range: 51-1345 106/kg)
were infused in the graft. The myeloid cell compart-
ment consists of large numbers of monocytes, various
numbers of dendritic cells, includingmyeloid and plas-
macytoid dendritic cells, and other not yet clearly de-
fined committed precursor cells.
CD3/19-depleted haploidentical PBSCs were
transplanted after RIC in 27 patients with various
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Children’s University Hospital Tu¨bingen. The condi-
tioning regimen consisted of Mephalan (140 mg/m2),
Thiotepa (10 mg/kg), Fludarabine (160 mg/m2), and
the murine anti-CD3 antibody OKT-3 and MMF.
Primary engraftment was seen in 23 patients (85%),
whereas 4 patients rejected the graft (15%). However,
all 4 patients could be rescued by a second transplant
using the other haploidentical donor and another
RIC regimen including total nodal irradiation, and
the final engraftment rate was 100%. A rapid engraft-
ment was seen with a median time to reach
.0.5 109/L neutrophils of 10 days (range: 9-12
days) and a median time to reach independency from
platelet transfusion of 8 days (range: 6-188 days).
Only 1 patient out of the 27 (4%) died from trans-
plant-related toxicity.
The HLA disparity of donor and recipients allows
a simple and detailed analysis of the engraftmentFigure 2. Flow cytometric analysis of CD341 positively selected stem cells an
homogenous without any contaminating non-T/B-cells, the CD3/19 depleted
cells, NK cells, and myeloid cells.status of various lymphocyte and myeloid cell popula-
tions [27]. Donor-derived cells can be easily identi-
fied using antibodies specific to the disparate HLA.
The flow cytometric chimerism analysis is rapid and
the results are obtained the same day. Especially in
situations with increasing recipient-derived T cell
populations, rapid action, such as decrease or stop
of immunusuppression or additional donor lympho-
cyte infusion can be taken.
To determine the functional status of the NK cells
in the grafts, the NK activity was measured in 11 do-
nors after mobilisation with granulocyte-colony stim-
ulating factor (G-CSF). As shown in Figure 3, the NK
activity of the CD3/19 depleted PBSCs against the
K562 standard target cell line is rather moderate, but
can be induced by an overnight incubation with IL-2
and most effectively by IL-15. Because IL-15 consis-
tently was most effective stimulating the NK cells in
CD3/19-depleted grafts, this approach was used ford CD3/19 negatively depleted PBSCs. Although the CD341 population is
PBSC’s contain large numbers of non- T/B-cells, including CD341 stem
Figure 3. The NK activity of PBSCs without and with overnight stimulation with IL-2 and IL-15 against the standard target cell line K562 is shown.
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large numbers of haploidentical NK cells using mobi-
lized PBSCs. An aliquot from the CD3/19-depleted
PBSCs was incubated overnight with 10 ng/mL IL-
15. NK activity of mobilized CD3/19 depleted grafts
of 6 donors before and after stimulation with IL-15 in-
creased on average 2- to 3-fold over baseline. Such IL-
15-activated NK cells were infused in 6 patients after
extensive washing steps to remove IL-15. The median
number of activated and infused CD561NK cells was
35 106/kg recipient body weight. The infusions were
well tolerated and no side effects were observed. To
test whether incubation of the CD3/19-depleted
PBSCs would influence the proliferative response of
the NK cells, the cells were extensively washed and in-
cubated with various stimuli. IL-15 preactivated cells
showed a much higher proliferative response to IL-2
compared to nonactivated cells, whereas the prolifera-
tive responses to other stimuli (PHA, PWM, Prot-A,
OKT-3, ConA) were less impressive.
These studies suggest that the early posttransplant
treatment with low dose IL-2 should induce an exten-
sive in vivo proliferation of IL-15-activated NK cells
coinfused together with the stem cells at day 0. Previ-
ous studies demonstrated that low-dose subcutaneous
IL-2 (1-2 106 IU/m2 3 times a week) post-T cell-
depleted allogeneic transplantation was well tolerated
without major side effects and without increase of
the risk of GVHD. In addition, there was a significant
increase of theNK activity a fewweeks after start of the
IL-2 treatment. Therefore, clinical studies using ex
vivo activation of CD3/19-depleted PBSC-containingNK cells with IL-15 and early in vivo posttransplant
treatment with IL-2 are under preparation.
In the future, haploidentical transplantation using
RIC and CD3/19-depleted mobilized PBSCs may be
viewed as a platform for further immunotherapeutic
strategies to enhance engraftment and to increase the
antimalignancy effect of the graft exerted by NK cells.
The mobilization regimen might have an influence on
theNK activity and other mobilization strategies, such
as the combination of G-CSG/granulocyte macro-
phage-colony stimulating factor (GM-CSF) or the
combination of growth factors with CXCR4-inhibi-
tors can be envisioned. The T cell depletion methods
can be improved, and we have already demonstrated
that the depletion of a/b-positive T-lymphocytes
leads to a more efficient T cell depletion compared
to CD3-depletion [28]. Such grafts would contain
large numbers of NK cells and g/d-T cells, which do
not cause GVHD and might exert significant antileu-
kemic effects[29,30]. These methods could be com-
bined with posttransplant therapeutic strategies to
further augment the cytotoxicity of the effector cells,
which are cotransfused with T cell-depleted PBSCs.
Such an approach could be the early posttransplant
treatment with low dose IL-2 or other immune-
augmenting substances. Further studies are necessary
to determine the clinical importance of other cell
populations in such T cell-depleted PBSCs, such as
dendritic or committed progenitor cells. Thus, the T
cell-depletion approach offers more graft-manipulat-
ing and immune-augmenting opportunities compared
to the CD341 positive selection approach. Future
S74 Biol Blood Marrow Transplant 16:S68-S74, 2010E. Guinan et al.clinical trials employing such strategies are warranted
to further improve the outcome of haploidentical
transplantation.ACKNOWLEDGMENTS
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